Dear Customer,
Genomica is pleased to announce the launch of FERTILADVANCE TESE, the first genetic test designed to identify monogenic causes of non-obstructive azoospermia (NOA) and to estimate the probability of sperm retrieval (predictive assessment of TESE/micro-TESE outcome) in support of clinical counselling.


Azoospermia (absence of spermatozoa in the ejaculate) is the most severe form of male infertility and affects approximately 1% of the male population. In clinical practice, NOA is among the most complex conditions in the management of male infertility: in many patients, the only option to obtain gametes suitable for ART (ICSI) is surgical retrieval via TESE/micro-TESE, which nevertheless fails in a substantial proportion of cases (≈50% in idiopathic series).

Clinical-hormonal parameters and first-line genetic tests (karyotype, Y-chromosome microdeletions) have limited prognostic value.

In recent years, Next Generation Sequencing (NGS) technologies have enabled the identification of monogenic determinants of NOA and, crucially, the correlation of specific genes with the likelihood of sperm retrieval.



FERTILADVANCE TESE is an advanced genetic test that integrates:

📍Molecular diagnosis of NOA
Identificazione di cause monogeniche associate a NOA/spermatogenic failure mediante l’analisi di 200+ geni coinvolti in processi chiave della spermatogenesi.

📍Prognostic stratification of TESE outcome (pre-TESE or after failed TESE)
When pathogenic variants are detected in specific genes with evidence supporting TESE−/TESE+ association, the test provides a prognostic estimate that can support clinical decision-making:

⚠️TESE-negative (very unfavorable prognosis): genes associated with a very low - often near-zero - probability of sperm retrieval in carriers of pathogenic variants.
→supports consideration of avoiding repeated procedures with an unfavorable risk/benefit ratio.
→supports discussion of alternative reproductive strategies (e.g., male donor sperm).

✅TESE-positive  genes in which pathogenic variants are compatible with residual sperm production and therefore with the possibility of retrieval.
→suggests partially preserved or intermittent spermatogenesis.
→TESE/micro-TESE may be clinically justified, with success being gene-dependent and influenced by clinical/histological factors.





Download FERTILADVANCE TESE informational brochure
by clicking on the image above

For more information about FERTILADVANCE TESE, please visit www.fertiladvance.it or contact our team of geneticists.
Our Scientific & Commercial Representative is available to discuss operational aspects and collaboration opportunities to integrate the test into clinical practice.
If you would like to receive a collaboration proposal or be connected with our local Scientific & Commercial Representative, please write to us:

Contact Genomica

We look forward to sharing the most advanced and innovative diagnostic solutions in the field of genetics.

GENOMICA srl
Marketing & Communication Department